MicroRNA and cancer drug resistance

Daohong Chen, Harikrishna Nakshatri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The last decade witnessed exponential growth in our understanding of the role of microRNAs (miRNAs) in cancer. In addition to a clearly defined role in cancer initiation and progression, miRNAs are now believed to determine sensitivity to therapy. The post-genomic era has seen rapid growth in our understanding of drug resistance mechanisms at the genomic level including genomic aberrations involving miRNA clusters and in the development of targeted therapies. Aberrant activity of a single miRNA can influence multiple signaling pathways associated with therapeutic response because it can target multiple proteins. Although it is difficult to pinpoint a single downstream effector of a miRNA, studies focusing on known oncogenes and tumor suppressors targeted by miRNA as well as advanced bioinformatics capabilities have enabled the discovery of integrated mRNA-miRNA-protein circuitry in cancer cells that govern multiple aspects of cancer including drug sensitivity. These studies have provided evidence for specific miRNAs targeting signaling molecules involved in drug transport, drug metabolism, synthesis of ligands for receptors, drug-induced DNA damage response and apoptotic pathways, and growth factor receptors/kinases/phosphatases that form the backbone of targeted therapies. Extensive knowledge of miRNA expression pattern and targets has allowed clinical translation of miRNAs as prognostic and predictive markers of therapies. miRNAs expressed in cancer cells govern signaling not only in cancer cells but also in neighboring cells and distant organs because they are incorporated into secretory microvesicles, remain stable in body fluids, and cross plasma membrane or cell-cell junctions. These properties of miRNAs have generated considerable interest in developing means to restore normal miRNA patterns in cancer through therapeutic approaches. Indeed, miRNA-based therapies are already in phase II clinical trial for hepatitis C infection, confirming feasibility of this approach. Therefore, miRNA or miRNA antagomir-based therapies are likely the next-revolutionary therapeutic approach to combat cancer.

Original languageEnglish (US)
Title of host publicationMicroRNA in Development and in the Progression of Cancer
PublisherSpringer New York
Pages305-326
Number of pages22
ISBN (Print)9781489980656, 1489980644, 9781489980649
DOIs
StatePublished - Jan 1 2014

Fingerprint

MicroRNAs
Drug Resistance
Neoplasms
Therapeutics
Pharmaceutical Preparations
Drug Receptors
Phase II Clinical Trials
Intercellular Junctions
Growth Factor Receptors
Body Fluids
Hepatitis C
Growth
Plasma Cells
Computational Biology
Oncogenes
Phosphoric Monoester Hydrolases
DNA Damage
Proteins

Keywords

  • Apoptosis
  • Biomarkers
  • Drug resistance
  • Drug transporters
  • MicroRNA
  • Signaling pathways
  • Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chen, D., & Nakshatri, H. (2014). MicroRNA and cancer drug resistance. In MicroRNA in Development and in the Progression of Cancer (pp. 305-326). Springer New York. https://doi.org/10.1007/978-1-4899-8065-6_16

MicroRNA and cancer drug resistance. / Chen, Daohong; Nakshatri, Harikrishna.

MicroRNA in Development and in the Progression of Cancer. Springer New York, 2014. p. 305-326.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chen, D & Nakshatri, H 2014, MicroRNA and cancer drug resistance. in MicroRNA in Development and in the Progression of Cancer. Springer New York, pp. 305-326. https://doi.org/10.1007/978-1-4899-8065-6_16
Chen D, Nakshatri H. MicroRNA and cancer drug resistance. In MicroRNA in Development and in the Progression of Cancer. Springer New York. 2014. p. 305-326 https://doi.org/10.1007/978-1-4899-8065-6_16
Chen, Daohong ; Nakshatri, Harikrishna. / MicroRNA and cancer drug resistance. MicroRNA in Development and in the Progression of Cancer. Springer New York, 2014. pp. 305-326
@inbook{1ae39927789747ad953f28ef460c49dd,
title = "MicroRNA and cancer drug resistance",
abstract = "The last decade witnessed exponential growth in our understanding of the role of microRNAs (miRNAs) in cancer. In addition to a clearly defined role in cancer initiation and progression, miRNAs are now believed to determine sensitivity to therapy. The post-genomic era has seen rapid growth in our understanding of drug resistance mechanisms at the genomic level including genomic aberrations involving miRNA clusters and in the development of targeted therapies. Aberrant activity of a single miRNA can influence multiple signaling pathways associated with therapeutic response because it can target multiple proteins. Although it is difficult to pinpoint a single downstream effector of a miRNA, studies focusing on known oncogenes and tumor suppressors targeted by miRNA as well as advanced bioinformatics capabilities have enabled the discovery of integrated mRNA-miRNA-protein circuitry in cancer cells that govern multiple aspects of cancer including drug sensitivity. These studies have provided evidence for specific miRNAs targeting signaling molecules involved in drug transport, drug metabolism, synthesis of ligands for receptors, drug-induced DNA damage response and apoptotic pathways, and growth factor receptors/kinases/phosphatases that form the backbone of targeted therapies. Extensive knowledge of miRNA expression pattern and targets has allowed clinical translation of miRNAs as prognostic and predictive markers of therapies. miRNAs expressed in cancer cells govern signaling not only in cancer cells but also in neighboring cells and distant organs because they are incorporated into secretory microvesicles, remain stable in body fluids, and cross plasma membrane or cell-cell junctions. These properties of miRNAs have generated considerable interest in developing means to restore normal miRNA patterns in cancer through therapeutic approaches. Indeed, miRNA-based therapies are already in phase II clinical trial for hepatitis C infection, confirming feasibility of this approach. Therefore, miRNA or miRNA antagomir-based therapies are likely the next-revolutionary therapeutic approach to combat cancer.",
keywords = "Apoptosis, Biomarkers, Drug resistance, Drug transporters, MicroRNA, Signaling pathways, Therapy",
author = "Daohong Chen and Harikrishna Nakshatri",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/978-1-4899-8065-6_16",
language = "English (US)",
isbn = "9781489980656",
pages = "305--326",
booktitle = "MicroRNA in Development and in the Progression of Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - MicroRNA and cancer drug resistance

AU - Chen, Daohong

AU - Nakshatri, Harikrishna

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The last decade witnessed exponential growth in our understanding of the role of microRNAs (miRNAs) in cancer. In addition to a clearly defined role in cancer initiation and progression, miRNAs are now believed to determine sensitivity to therapy. The post-genomic era has seen rapid growth in our understanding of drug resistance mechanisms at the genomic level including genomic aberrations involving miRNA clusters and in the development of targeted therapies. Aberrant activity of a single miRNA can influence multiple signaling pathways associated with therapeutic response because it can target multiple proteins. Although it is difficult to pinpoint a single downstream effector of a miRNA, studies focusing on known oncogenes and tumor suppressors targeted by miRNA as well as advanced bioinformatics capabilities have enabled the discovery of integrated mRNA-miRNA-protein circuitry in cancer cells that govern multiple aspects of cancer including drug sensitivity. These studies have provided evidence for specific miRNAs targeting signaling molecules involved in drug transport, drug metabolism, synthesis of ligands for receptors, drug-induced DNA damage response and apoptotic pathways, and growth factor receptors/kinases/phosphatases that form the backbone of targeted therapies. Extensive knowledge of miRNA expression pattern and targets has allowed clinical translation of miRNAs as prognostic and predictive markers of therapies. miRNAs expressed in cancer cells govern signaling not only in cancer cells but also in neighboring cells and distant organs because they are incorporated into secretory microvesicles, remain stable in body fluids, and cross plasma membrane or cell-cell junctions. These properties of miRNAs have generated considerable interest in developing means to restore normal miRNA patterns in cancer through therapeutic approaches. Indeed, miRNA-based therapies are already in phase II clinical trial for hepatitis C infection, confirming feasibility of this approach. Therefore, miRNA or miRNA antagomir-based therapies are likely the next-revolutionary therapeutic approach to combat cancer.

AB - The last decade witnessed exponential growth in our understanding of the role of microRNAs (miRNAs) in cancer. In addition to a clearly defined role in cancer initiation and progression, miRNAs are now believed to determine sensitivity to therapy. The post-genomic era has seen rapid growth in our understanding of drug resistance mechanisms at the genomic level including genomic aberrations involving miRNA clusters and in the development of targeted therapies. Aberrant activity of a single miRNA can influence multiple signaling pathways associated with therapeutic response because it can target multiple proteins. Although it is difficult to pinpoint a single downstream effector of a miRNA, studies focusing on known oncogenes and tumor suppressors targeted by miRNA as well as advanced bioinformatics capabilities have enabled the discovery of integrated mRNA-miRNA-protein circuitry in cancer cells that govern multiple aspects of cancer including drug sensitivity. These studies have provided evidence for specific miRNAs targeting signaling molecules involved in drug transport, drug metabolism, synthesis of ligands for receptors, drug-induced DNA damage response and apoptotic pathways, and growth factor receptors/kinases/phosphatases that form the backbone of targeted therapies. Extensive knowledge of miRNA expression pattern and targets has allowed clinical translation of miRNAs as prognostic and predictive markers of therapies. miRNAs expressed in cancer cells govern signaling not only in cancer cells but also in neighboring cells and distant organs because they are incorporated into secretory microvesicles, remain stable in body fluids, and cross plasma membrane or cell-cell junctions. These properties of miRNAs have generated considerable interest in developing means to restore normal miRNA patterns in cancer through therapeutic approaches. Indeed, miRNA-based therapies are already in phase II clinical trial for hepatitis C infection, confirming feasibility of this approach. Therefore, miRNA or miRNA antagomir-based therapies are likely the next-revolutionary therapeutic approach to combat cancer.

KW - Apoptosis

KW - Biomarkers

KW - Drug resistance

KW - Drug transporters

KW - MicroRNA

KW - Signaling pathways

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84930335398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930335398&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-8065-6_16

DO - 10.1007/978-1-4899-8065-6_16

M3 - Chapter

SN - 9781489980656

SN - 1489980644

SN - 9781489980649

SP - 305

EP - 326

BT - MicroRNA in Development and in the Progression of Cancer

PB - Springer New York

ER -